Cardiovascular Business November 18, 2024
2. CRISPR therapy for transthyretin amyloidosis
This phase 1 study explored the potential of in vivo CRISPR technology to treat transthyretin amyloidosis with cardiomyopathy (ATTR-CM) using nexiguran ziclumeran (nex-z, also known as NTLA-2001). The study used a single four-hour infusion of altered liver cells to address the gene responsible for amyloid production. Early results suggest promise for future treatments targeting the root cause rather than symptom management.
3. Edoxaban in bioprosthetic surgical valve replacement (ENBALV Trial)
This study compared edoxaban, a novel oral anticoagulant (NOAC), to traditional warfarin in patients with surgical bioprosthetic valves. Edoxaban was as effective as warfarin in preventing thromboembolic events without increasing bleeding risks. Wilson said this is potentially a game-changer due to its ease of...
Today's Sponsors
Today's Sponsor